Citations

Clear

1575 citation(s) found for "Im, Gene".

NCOG-38. UNDERSTANDING GLIOMA IN LI-FRAUMENI SYNDROME: HIGHLIGHTING THE VALUE OF SCREENING AND GENE SEQUENCING
Padilla, Hannah, Carabenciov, Ivan D. , Uhm, Joon H. , Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v222-v222

10.1093/neuonc/noad179.0851 Get It

Abstract Li-Fraumeni Syndrome (LFS) is a rare autosomal dominant disorder characterized by a germline mutation in the TP53 gene that confers an increased risk of developing cancers, including brain tumors. There is continued need to understand how LFS diagnosis impacts clinical management and outcomes of gliomas. We report the clinical course of two patients from our Neuro-Oncology. Patient 1 is a male who was diagnosed with a low-grade astrocytoma, IDH1 mutant at age 20 status post gross total resection. Given radiographic concern for tumor progression, he underwent re-resection 8 years later. Pathology showed gliosis with TP53-mutant cells. Next-generation sequencing (NGS) was positive a germline TP53 mutation, consistent with LFS. He is currently in surveillance 12 years after diagnosis without need for radiation or chemotherapy. Patient 2 is a female who was diagnosed with glioblastoma, IDH wildtype, MGMT promoter unmethylated at age 40. She was asymptomatic at the time of diagnosis as the tumor was found during routine screening. She underwent gross total resection, radiation with concurrent and adjuvant temozolomide. She is now 5 years from last treatment without recurrence. These cases illustrate the clinical spectrum of glioma in LFS. Both patients have had prolonged periods of survival without progression, even accounting for respective tumor type. Patient 1 was only diagnosed with LFS after radiographic concerns for progression. Using NGS to diagnosis LFS was clinically important, as previous reports have shown greater propensity for malignant transformation of low-grade glioma in LFS. Patient 2 was diagnosed with glioblastoma during screening and has had no recurrence. This highlights the value of early diagnosis and treatment of gliomas in patients with LFS, even if asymptomatic at discovery. Further research is needed to understand the clinical spectrum of glioma in LFS and to optimize the care of this unique patient population.
Machine Learning Analysis of Gene Expression Reveals TP53 Mutant-like AML With Wild Type TP53 And Poor Prognosis
Baughn, Linda B. , Myers, Chad L. , Baughn, Linda B , Sachs, Zohar , Lee, Yoonkyu

Mayo Clinic

No container title available | November 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3575623/v1 Get It

Abstract Acute myeloid leukemia (AML) with TP53 mutations (TP53Mut) has poor clinical outcomes. We investigated whether this AML subtype harbors a distinct gene expression profile (GEP) and whether this GEP is prognostic in TP53 wild type (TP53WT) AML. We applied a supervised machine-learning approach to detect the TP53Mut GEP. We divided the samples in the Beat-AML dataset into training and testing datasets. The TCGA LAML dataset was used as a validation dataset. We trained a ridge regression machine learning model to classify TP53Mut and TP53WT cases. This model was highly accurate in distinguishing TP53Mut versus TP53WT cases in both the test and validation datasets. Additionally, we identified TP53WT samples with high ridge regression scores. These high-scoring TP53WT samples also have poor overall survival, suggesting they share clinical and GEP features with TP53Mut AML. We defined these TP53WT samples as TP53Mut-like. Using drug sensitivity data in the Beat AML dataset, we found TP53Mut-like AMLs have distinct drug sensitivity patterns that phenocopy TP53Mut cases. Finally, we identified a 25-gene signature that can identify TP53Mut-like AML. This signature could be used clinically to identify this novel subset of poor-prognosis AML.
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs
Nijenhuis, Marga , Manson, Lisanne E. N. , Soree, Bianca, Boer-Veger, Nienke de, Buunk, Anne M. , Houwink, Elisa J. F. , Risselada, Arne, Rongen, Gerard A. , Schaik, Ron HN van , Swen, Jesse J. , Westrhenen, Roos van , Deneer, Vera H.M. , Houwink, Elisa J F , Boer‐Veger, Nienke J. de, Touw, Daan Johannes , Guchelaar, Henk‐Jan

Mayo Clinic

No container title available | November 8, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3255043/v1 Get It

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the gene-drug interaction of CYP2C9 and HLA-B with phenytoin, HLA-A and HLA-B with carbamazepine and HLA-B with oxcarbazepine and lamotrigine. A systematic review was performed and pharmacotherapeutic recommendations were developed. For CYP2C9 intermediate and poor metabolisers, the DPWG recommends lowering the daily dose of phenytoin and adjust based on effect and serum concentration after 7–10 days. For HLA-B*15:02 carriers, the risk of severe cutaneous adverse events associated with phenytoin, carbamazepine, oxcarbazepine and lamotrigine is strongly increased. For carbamazepine, this risk is also increased in HLA-B*15:11 and HLA-A*31:01 carriers. For HLA-B*15:02, HLA-B*15:11 and HLA-A*31:01 positive patients, the DPWG recommends choosing an alternative anti-epileptic drug. If not possible, it is recommended to advise the patient to report any rash while using carbamazepine, lamotrigine, oxcarbazepine or phenytoin immediately. Carbamazepine should not be used in an HLA-B*15:02 positive patient. DPWG considers CYP2C9 genotyping before the start of phenytoin “essential” for toxicity prevention. For patients with an ancestry in which the abovementioned HLA-alleles are prevalent, the DPWG considers HLA-B*15:02 genotyping before the start of carbamazepine, phenytoin, oxcarbazepine and lamotrigine “beneficial”, as well as genotyping for HLA-B*15:11 and HLA-A*31:01 before initiating carbamazepine.
DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands
Walker, Romy , Mahmood, Khalid , Como, Julia , Joo, Jihoon E. , Georgeson, Peter , Joseland, Sharelle , Preston, Susan , Pope, Bernard J. , Chan, James , Austin, Rachel , Bojadzieva, Jasmina , Campbell, Ainsley , Edwards, Emma, Goodwin, Annabel , Harris, Marion , Ip, Emilia , Kirk, Judy , Mansour, Julia, Fan, Helen Mar , Nichols, Cassandra , Pachter, Nicholas , Ragunathan, Abiramy, Spigelman, Allan D. , Susman, Rachel , Pai, Rish K. , Rosty, Christophe , Winship, Ingrid , Buchanan, Daniel D. , Pope, Bernard J , Chan, James M , Winship, Ingrid M , Buchanan, Daniel D , Rosty, Christophe , Georgeson, Peter , Clendenning, Mark , Gleeson, Margaret A. , Christie, Michael , Jenkins, Mark A. , Macrae, Finlay

Mayo Clinic

Cancers | October 10, 2023 | Volume: 15 | Issue: 20 | Pages: 4925

10.3390/cancers15204925 | PMID 37894291 Get It

Germline pathogenic variants in the DNA mismatch repair (MMR) genes (Lynch syndrome) predispose to colorectal (CRC) and endometrial (EC) cancer. Lynch syndrome specific tumor features were evaluated for their ability to support the ACMG/InSiGHT framework in classifying variants of uncertain clinical significance (VUS) in the MMR genes. Twenty-eight CRC or EC tumors from 25 VUS carriers (6xMLH1, 9xMSH2, 6xMSH6, 4xPMS2), underwent targeted tumor sequencing for the presence of microsatellite instability/MMR-deficiency (MSI-H/dMMR) status and identification of a somatic MMR mutation (second hit). Immunohistochemical testing for the presence of dMMR crypts/glands in normal tissue was also performed. The ACMG/InSiGHT framework reclassified 7/25 (28%) VUS to likely pathogenic (LP), three (12%) to benign/likely benign, and 15 (60%) VUS remained unchanged. For the seven re-classified LP variants comprising nine tumors, tumor sequencing confirmed MSI-H/dMMR (8/9, 88.9%) and a second hit (7/9, 77.8%). Of these LP reclassified variants where normal tissue was available, the presence of a dMMR crypt/gland was found in 2/4 (50%). Furthermore, a dMMR endometrial gland in a carrier of an MSH2 exon 1-6 duplication provides further support for an upgrade of this VUS to LP. Our study confirmed that identifying these Lynch syndrome features can improve MMR variant classification, enabling optimal clinical care.
The expanding universe of gene and cell therapy
Tichy, Eric M.

Mayo Clinic

American Journal of Health-System Pharmacy | October 4, 2023 | Volume: 80 | Issue: 23 | Pages: 1685-1685

10.1093/ajhp/zxad251 | PMID 37793131 Get It

Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies
Lee, Jae , Knievel, Kerry, McVige, Jennifer , Wang, Weiying , Gillard, Patrick, Shah, Darshini, Blumenfeld, Andrew , Schwedt, Todd J. , Wu, Zheng

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 10 | Pages: 1119-1128

10.18553/jmcp.2023.29.10.1119 | PMID 37776119 Get It

A-145 Development of a Novel Algorithm Using Red Blood Cell Indices for Screening of Alpha Globin Gene Deletions
Zhang, Xiongfeng , Oliveira, João Ricardo Mendes de , Parikh, Bijal A.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.132 Get It

Abstract Background Distinguishing between different causes of microcytic anemia is essential for management of anemic patients. More than 20 different RBC indices have been used to screen thalassemia trait with inconsistent results. Differentiation between iron deficiency anemia (IDA) and alpha-thalassemia is challenging based on RBC indices alone. Moreover, thalassemia and IDA may coexist. A highly sensitive screening algorithm is needed to select clinical cases for alpha globin gene analysis to reduce unnecessary testing and improve pre-test probabilities. Methods A retrospective study was performed to evaluate the reliability of 22 RBC indices (RBC, MCV, RDW, MCH, Mentzer Index, RDW Index, etc) and formulae in differentiating cases with 1–2 alpha globin gene deletions from negative cases, in a cohort of 90 individuals with confirmatory alpha globin gene analysis results. Results The number of patients with each alpha globin gene deletion pattern were: 37 patients with alpha-thalassemia trait, 21 silent carriers (one gene deletion), 31 patients with negative result and 1 patient with triplicated alpha globin gene. The mean RBC count in each group were 4.79 ± 0.65 (trait), 4.45 ± 0.73 (carrier), and 4.21 ± 0.84 (negative) (million/mm). The mean MCV in each group were 71.1 ± 4.8 (trait), 76.1 ± 5.9 (carrier), and 74.2 ± 9.3 (negative) (fL). The mean RDW in each group were 16.5 ± 3.0 (trait), 17.2 ± 3.4 (carrier), and 18.3 ± 4.9 (negative) (%). The mean MCH in each group were 22.0 ± 1.8 (trait), 23.8 ± 2.3 (carrier), and 23.5 ± 3.7 (negative) (pg). None of the RBC indices showed significant difference between carrier and negative groups, while 20 RBC indices showed significant difference (P < 0.05) between trait and negative groups. The sensitivities of the RBC indices in detecting 1–2 alpha globin gene deletions based on published cut-offs ranged between 3.4% and 81.0%, while the specificities ranged between 41.9% and 100%. A novel scoring algorithm was evaluated based on the combination of 12 selected RBC indices and formulae, with each index or formula contributing to a score of 0 or 1. The average value of the negative cases was used as the score cut-off value for each index or formula. The scoring algorithm gave a score distribution between 0 and 12, with lower scores indicating alpha globin gene deletions. It achieved a sensitivity of 96.6% in detecting 1–2 alpha globin gene deletions, with a negative likelihood ratio of 0.15. The negative likelihood ratio of the scoring algorithm outperformed each of the individual RBC indices at similar levels of sensitivities (>95%). Conclusion The novel algorithm is a highly sensitive tool for screening of alpha globin gene deletions, including one gene deletion. It is more effective at identifying negative cases compared to individual RBC indices. Implementation of the algorithm could efficiently reduce 10.0% (9/90) of the test volume of alpha globin gene analysis. A more stringent version of the algorithm that incorporates standard deviation in the cut-off values could potentially achieve nearly 100% sensitivity and reduce 5.6% (5/90) of the alpha globin gene analysis test volume.
Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer
Saunders, Edward J. , Sheng, Xin , Wan, Peggy , Pooler, Loreall , Xia, Lucy , Chanock, Stephen, Berndt, Sonja I., Patel, Alpa V. , Albanes, Demetrius, Weinstein, Stephanie J. , Gnanapragasam, Vincent J. , Huff, Chad D. , Pomerantz, Mark M., Schmidt, Julie A. , Travis, Ruth C. , Mucci, Lorelei A. , Catàlona, William J. , Marosy, Beth, Hetrick, Kurt N. , Doheny, Kimberly F. , MacInnis, Robert J. , Eeles, Rosalind A. , Kote‐Jarai, Zsofia , Haiman, Christopher A. , Eeles, Rosalind A , Travis, Ruth C , Maclnnis, Robert , Darst, Burcu F. , Dadaev, Tokhir , Berndt, Sonja I. , Wang, Ying , Couch, Fergus J. , Wolk, Alicja , Giles, Graham G. , Nguyen‐Dumont, Tú , Milne, Roger L. , Key, Tim , Stopsack, Konrad H. , Southey, Melissa C. , Wiklund, Fredrik E. , Conti, David V.

Mayo Clinic

JAMA Oncology | September 21, 2023 | Volume: 9 | Issue: 11 | Pages: 1514

10.1001/jamaoncol.2023.3482 | PMID 37733366 Get It

Importance Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. Objective To identify genes associated with aggressive PCa. Design, Setting, and Participants A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa. Exposure Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels. Main Outcomes and Measures The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa. Results A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM ( P ≤ 1.9 × 10 −6 ), followed by NBN ( P = 1.7 × 10 −4 ). This study found nominal evidence ( P < .05) of association with rare deleterious variants in MSH2 , XRCC2 , and MRE11A . Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53 , RAD51D , BARD1 , GEN1 , and SLX4 . Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa. Conclusions and Relevance The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease.
From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies
Crotti, Lia , Brugada, Pedro , Calkins, Hugh , Chevalier, Philippe , Conte, Giulio , Finocchiaro, Gherardo , Postema, Pieter G. , Probst, Vincent , Schwartz, Peter J. , Behr, Elijah R. , Schwartz, Peter J. , Crotti, Lia , Behr, Elijah Raphael , Probst, Vincent , Conte, Giulio , Postema, Pieter G

Mayo Clinic

Europace | August 25, 2023 | Volume: 25 | Issue: 8 | Pages: No page available

10.1093/europace/euad180 | PMID 37622577 Get It

Abstract In the early nineties, few years before the birth of Europace, the clinical and scientific world of familial arrhythmogenic conditions was revolutionized by the identification of the first disease-causing genes. The explosion of genetic studies over a 15-year period led to the discovery of major disease-causing genes in practically all channelopathies and cardiomyopathies, bringing insight into the pathophysiological mechanisms of these conditions. The birth of next generation sequencing allowed a further step forward and other significant genes, as CALM1–3 in channelopathies and FLN C and TTN in cardiomyopathies were identified. Genotype–phenotype studies allowed the implementation of the genetic results in diagnosis, risk stratification, and therapeutic management with a different level of evidence in different arrhythmogenic conditions. The influence of common genetic variants, i.e. SNPs, on disease manifestation was proved in mid-twenties, and in the last 10 years with the advent of genome-wide association studies performed in familial arrhythmogenic diseases, the concept of polygenic risk score has been consolidated. Now, we are at the start of another amazing phase, i.e. the initiation of first gene therapy clinical trials.
A Primer on Gene Editing: What Does It Mean for Pathologists?
Cushman‐Vokoun, Allison M. , Schmidt, Ryan J. , Hiemenz, Matthew , Zhang, Bing , Bradshaw, Georganne, Yao, JinJuan , Yohe, Sophia , Beckman, Amy , Grody, Wayne W., Giannikopoulos, Petros , Fung, Mark K , Gandhi, Manish J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 21, 2023 | Volume: 148 | Issue: 5 | Pages: 515-530

10.5858/arpa.2022-0410-cp | PMID 41386658 Get It

Context Gene editing–based therapies are currently in development in the areas of oncology, inherited disease, and infectious disease. These potentially life-altering therapies are derived from decades of research in both academic and industry settings that developed technologies rooted in principles and products of nature. However, with such technologic developments come many important considerations, including adverse risks, high cost, and ethical questions. Objective To educate pathologists about gene editing technologies, inform them of potential indications and risks, outline regulatory and practical issues that could affect hospital-based practice and laboratory testing, and advocate that pathologists need to be present at discussions among industry and regulators pertaining to gene editing–based therapies. Design A Gene Editing Workgroup, facilitated by the College of American Pathologists Personalized Health Care Committee and consisting of pathologists of various backgrounds, was convened to develop an educational paper to serve as a stimulus to increase pathologist involvement and inquiry in gene editing therapeutic and diagnostic implementation. Results Through multiple discussions and literature review, the workgroup identified potential gaps in pathologists' knowledge of gene editing. Additional topics that could impact pathology and laboratory medicine were also identified and summarized in order to facilitate pathologists as stakeholders in gene editing therapy administration and monitoring and potential use in diagnostics. Conclusions Gene editing therapy is a complex but potentially transformative area of medicine. This article serves as an introduction to pathologists to assist them in future discussions with colleagues and potentially identify and alter pathology practices that relate to gene editing.